Results 101 to 110 of about 360 (160)

Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma. [PDF]

open access: yesFuture Oncol
Leypoldt LB   +26 more
europepmc   +1 more source

Advanced disease and CD8<sup>+</sup> TEMRA cells predict severe infections in multiple myeloma. [PDF]

open access: yesFront Immunol
Tranter E   +9 more
europepmc   +1 more source

Functional cortical localization of tongue movements using corticokinematic coherence with a deep learning-assisted motion capture system. [PDF]

open access: yesSci Rep, 2022
Maezawa H   +7 more
europepmc   +1 more source

Immunotherapy approaches for hematological cancers. [PDF]

open access: yesiScience, 2022
Lanier OL   +8 more
europepmc   +1 more source

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. [PDF]

open access: yesJ Clin Oncol
Leypoldt LB   +26 more
europepmc   +1 more source

Real-world analysis of teclistamab in 123 RRMM patients from Germany. [PDF]

open access: yesLeukemia
Riedhammer C   +25 more
europepmc   +1 more source

Population data of 23 Y chromosome STR loci for Kyrgyz population from Kyrgyzstan. [PDF]

open access: yesData Brief
Isakova Z   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy